natgillin/translations-raw huggingface dataset:
M-M-RVAXPRO is to be used on the basis of official recommendations.
Cepljenje z M- M- RVAXPRO je treba izvajati v skladu z uradnimi priporočili.
Individuals 12 months or older should receive one dose at an elected date.
Starost nad 12 mesecev
The second dose is intended for individuals who did not respond to the first dose for any reason.
Drugi odmerek je namenjen osebam, ki se iz kakršnegakoli vzroka niso odzvale na prvo cepljenje.
Infants between 6 months and less than 12 months
2 Dojenčki, stari od 6 do 12 mesecev
No data on the efficacy and safety of M-M-RVAXPRO for use in children below 12 months are currently available (see section 5.1).
Podatkov o učinkovitosti in varnosti cepiva M- M- RVAXPRO za uporabo pri otrocih, mlajših od 12 mesecev, trenutno ni na voljo (glejte poglavje 5. 1).
Infants between 6 months and less than 12 months vaccinated with a measles-containing vaccine during measles outbreak or vaccinated at that age in accordance with official recommendation may fail to respond to the vaccine due to the presence of circulating antibodies of maternal origin.
Pri dojenčkih, starih od 6 do manj kot 12 mesecev, ki so med izbruhom ošpic cepljeni s cepivom, ki vsebuje cepivo proti ošpicam, ali ki so v tej starosti cepljeni v skladu z uradnimi priporočili, lahko zaradi prisotnosti materinih protiteles v obtoku ne pride do odziva na cepivo.
Such infants should be revaccinated at 12 to 15 months followed by an additional dose with a measles-containing vaccine according to the official recommendations.
Te otroke je treba ponovno cepiti v starosti od 12 do 15 mesecev, za tem pa še z dodatnim odmerkom cepiva, ki vsebuje cepivo proti ošpicam, v skladu z uradnimi priporočili.
The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC).
Cepivo je treba injicirati intramuskularno (i. m.) ali subkutano (s. c.).
The vaccine should be administered subcutaneously in patients with thrombocytopenia or any coagulation disorder.
Pri bolnikih s trombocitopenijo ali kakršnokoli drugo motnjo koagulacije je potrebno cepivo injicirati subkutano.
See section 6.6 for preparation instructions.
Za navodila za pripravo glejte poglavje 6. 6.
History of hypersensitivity to any measles, mumps, or rubella vaccine, or to any of the excipients, including neomycin (see sections 2, 4.4, and 6.1).
Preobčutljivost v anamnezi za katerokoli cepivo proti ošpicam, mumpsu ali rdečkam, ali za katerokoli pomožno snov, vključno z neomicinom (glejte poglavja 2, 4. 4 in 6. 1).
Pregnancy (see also sections 4.4 and 4.6).
Nosečnost (glejte tudi poglavji 4. 4 in 4. 6).
Vaccination should be postponed during any illness with fever > 38.5°C.
Cepljenje je treba odložiti pri katerikoli bolezni z zvišano telesno temperaturo > 38, 5 °C.
Active untreated tuberculosis (see section 4.4).
Aktivna nezdravljena tuberkuloza (glejte poglavje 4. 4).
Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems.
Krvne diskrazije, levkemija, katerakoli vrsta limfoma ali druga maligna novotvorba, ki vpliva na hematopoetski in limfatični sistem.
Current immunosuppressive therapy (including high doses of corticosteroids).
Trenutno imunosupresivno zdravljenje (vključno z velikimi odmerki glukokortikoidov).
M-M-RVAXPRO is not contraindicated in individuals who are receiving topical or low-dose parenteral corticosteroids (e. g. for asthma prophylaxis or replacement therapy).
M- M- RVAXPRO ni kontraindiciran pri posameznikih, ki prejemajo topikalne glukokortikoide ali majhne odmerke parenteralnih glukokortkoidov (npr. za preprečevanje astme ali kot nadomestno zdravljenje).
In severely immunocompromised individuals
Humoralna ali celična (primarna ali pridobljena) imunska pomankljivost, vključno s hipogamaglobulinemijo, disgamaglobulinemijo in aidsom, simptomatska okužba z virusom HIV ali starostno specifični odstotek CD4+ T- limfocitov < 25% (glejte poglavje 4. 4).
3 inadvertently vaccinated with measles-containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported.
Pri imunsko hudo oslabljenih osebah, ki so jih pomotoma cepili s cepivom proti ošpicam, so poročali o ošpičnem encefalitistu z inkluzijskimi telesci, o pnevmonitisu in smrti kot neposredni posledici razsejane okužbe s cepilnim virusom ošpic.
Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.
Vedno morajo biti na voljo ustrezne možnosti za zdravljenje in nadzor, če bi po cepljenju prišlo do sicer redke anafilaktične reakcije.
Adults and adolescents with a history of allergies may potentially be at increased risk of anaphylaxis or anaphylactoid reactions.
Odrasli in mladostniki z anamnezo alergij, imajo večjo možnost za nastanek anafilaktičnih ali anafilaktoidnih reakcij.
Since live measles vaccine and live mumps vaccine are produced in chick embryo cell culture, persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e. g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions.
Ker sta živo cepivo proti ošpicam in živo cepivo proti mumpsu pridobljeni iz celičnih kultur piščančjih zarodkov, so lahko osebe z anamnezo anafilaktične, anafilaktoidne ali druge takojšnje reakcije (npr. koprivnica, oteklina ust in grla, težave pri dihanju, hipotenzija ali šok) po zaužitju jajc izpostavljene večjemu tveganju takojšnjih preobčutljivostnih reakcij.
The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination in such cases.
V takih primerih je treba skrbno oceniti morebitno tveganje in korist, preden bi se odločili za cepljenje.
Due caution should be employed in administration of M-M-RVAXPRO to persons with individual or family history of convulsions, or a history of cerebral injury.
Ustrezna previdnost je potrebna, kadar s cepivom M- M- RVAXPRO cepimo osebe z osebno ali družinsko anamnezo konvulzij ali anamnezo poškodbe možganov.
The physician should be alert to the temperature elevation that may occur following vaccination (see section 4.8).
Zdravnik mora biti pozoren na morebitno zvišanje telesne temperature po cepljenju (glejte poglavje 4. 8).
The vaccine contains 1.9 mg of sucrose as an excipient.
Cepivo vsebuje 1, 9 mg saharoze, kot pomožno snov.
This amount is too low to cause adverse events in patients with rare hereditary problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.
Ta količina je premajhna, da bi pri bolnikih z redkimi dednimi težavami kot so intoleranca za fruktozo, malabsorbcija glukoze/ galaktoze ali pomanjkanje saharoze- izomaltaze povzročila neželene učinke.
The vaccine contains residual traces of recombinant human albumin (rHA).
V sledeh je v cepivu prisoten rekombinantni humani albumin (rHA).
In a study with children receiving a second dose of M-M-RVAXPRO, sensitisation to rHA was not observed.
V študiji pri otrocih, ki so prejeli drugi odmerek cepiva M- M- R VAXPRO, senzibilizacije na rHA niso opazili.
A theoretical risk of hypersensitivity to rHA at a low frequency cannot be ruled out.
Teoretičnega tveganja za preobčutljivost za rHA z nizko pogostnostjo ne moremo izključiti.
Therefore caution needs to be exercised when using any product containing rHA in individuals who previously showed signs of hypersensitivity to rHA.
Zato je pri posameznikih, pri katerih so se kdaj pokazali znaki preobčutljivosti za rHA, potrebna previdnost pri uporabi kateregakoli zdravila, ki vsebuje rHA.
Pregnancy The vaccine should not be administered to pregnant females; furthermore, pregnancy should be avoided for 3 months following vaccination (see sections 4.3 and 4.6).
Poleg tega ženske ne smejo zanositi še 3 mesece po cepljenju (glejte poglavje 4. 3 in 4. 6).
Thrombocytopenia This vaccine should be given subcutaneously to individuals with thrombocytopenia or any coagulation disorder because bleeding may occur following an intramuscular administration in these individuals.
Trombocitopenija Pri bolnikih s trombocitopenijo ali kakršnokoli drugo motnjo koagulacije je potrebno cepivo aplicirati subkutano, saj bi pri intramuskularni aplikaciji lahko prišlo do krvavitev.
Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination.
Pri osebah s trombocitopenijo se lahko ta po cepljenju poslabša.
In addition, individuals who experienced thrombocytopenia with the first dose of M-M-RVAXPRO (or its component vaccines) may develop thrombocytopenia with repeat doses.
Poleg tega se lahko pri osebah, pri katerih se je trombocitopenija pojavila po prvem cepljenju z M- M- RVAXPRO (ali s cepivi, ki ga sestavljajo), trombocitopenija pojavi po ponovnih odmerkih.
Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed.
Potrebne so serološke preiskave, s katerimi ocenimo, ali je ponovno cepljenje potrebno ali ne.
The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination in such cases (see section 4.8).
V takih primerih je treba skrbno pretehtati razmerje med morebitnim tveganjem in koristjo, preden se odločimo za cepljenje (glejte poglavje 4. 8).
4 Other Individuals who are known to be infected with human immunodeficiency viruses and are not immunocompromised may be vaccinated.
Drugo Osebe, za katere vemo, da so okužene z virusom HIV, in nimajo oslabljene imunosti, lahko cepimo.
However, these vaccinees should be monitored closely for measles, mumps, and rubella because vaccination may be less effective in these patients than in persons not infected with human immunodeficiency viruses (see section 4.3).
Vendar pa je treba te cepljene osebe pozorno spremljati v zvezi z ošpicami, mumpsom in rdečkami, saj je cepljenje pri teh bolnikih lahko manj učinkovito kot pri osebah, ki niso okužene s HIV (glejte poglavje 4. 3)
Children under treatment for tuberculosis have not experienced exacerbation of the disease when vaccinated with live measles virus vaccine; no studies have been reported to date on the effect of measles virus vaccines on children with untreated tuberculosis (see section 4.3).
Doslej niso poročali o študijah o vplivu cepiv proti ošpicam na otroke z nezdravljeno tuberkulozo (glejte poglavje 4. 3).
As for any vaccine, vaccination with M-M-RVAXPRO may not result in protection in all vaccinees.
Kot pri drugih cepivih je tudi pri cepljenju s cepivom M- M- RVAXPRO mogoče, da zaščita vseh cepljenih posameznikov ni popolna.
Transmission Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination.
4 Pri večini cepljenih, za rdečke dovzetnih posameznikov je 7 do 28 dni po cepljenju prišlo do izločanja majhnih količin živega oslabljenega virusa rdečk iz nosu ali grla.
Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk; however, transmission of the rubella vaccine virus to infants via breast milk has been documented without any evidence of clinical disease (see section 4.6).
Zato prenosa s tesnim osebnim stikom, ki je teoretično možen, nimamo za zelo tveganega; dokumentirali pa so prenos cepilnega virusa rdečk na dojenčka z materinim mlekom, brez kliničnih znakov bolezni (glejte poglavje 4. 6).
There are no reports of transmission of the more attenuated Enders’ Edmonston strain of measles virus or the Jeryl Lynn ™ strain of mumps virus from vaccinees to susceptible contacts.
Ni poročil o prenosu bolj oslabljenega seva virusa ošpic Enders 'Edmonston ali seva virusa mumpsa Jeryl Lynn™ s cepljenih oseb na kontaktne osebe, dovzetne za okužbo z virusom ošpic in mumpsa.
Immune globulin (IG) is not to be given concomitantly with M-M-RVAXPRO.
Sočasno s cepivom M- M- RVAXPRO ne dajajte imunoglobulinov (IG).
Administration of immune globulins concomitantly with M-M-RVAXPRO may interfere with the expected immune response.
Dajanje imunoglobulinov sočasno s cepivom M- M- RVAXPRO lahko ovira pričakovani imunski odziv.
Administration of measles, mumps, or rubella antibody-containing blood products, including immune globulin preparations, should be avoided within 1 month after a dose of M-M-RVAXPRO unless considered to be essential.
1 mesec po cepljenju z M- M- RVAXPRO se je treba izogibati dajanju krvnih pripravkov, ki vsebujejo protitelesa proti ošpicam, mumpsu ali rdečkam, vključno s pripravki imunoglobulinov, razen če je to nujno potrebno.
It has been reported that live attenuated measles, mumps, and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity.
Opisano je bilo, da lahko cepljenje s posameznimi oslabljenimi živimi cepivi proti ošpicam, mumpsu in rdečkam začasno zmanjša kožno občutljivost na tuberkulin.
Therefore, if a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or 4 to 6 weeks after vaccination with M-M-RVAXPRO.
Če načrtujete tuberkulinski test, ga je treba opraviti kadarkoli pred cepljenjem s cepivom M- M- RVAXPRO, hkrati z njim ali vsaj 4 do 6 tednov po njem.
Use with other vaccines Published clinical data support concomitant administration of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. with other childhood vaccinations, including DTaP (or DTwP), IPV (or OPV), HIB (Haemophilus influenzae type b), HIB-HBV (Haemophilus influenzae type b with Hepatitis B vaccine), and VAR (varicella).
Uporaba z drugimi cepivi Objavljeni klinični podatki podpirajo sočasno cepljenje s prejšnjo obliko cepiva proti ošpicam, mumpsu in rdečkam proizvajalca Merck & Co., Inc. in z drugimi otroškimi cepivi, vključno z DTaP (ali DTwP), IPV (ali OPV), HIB (Haemophilus influenzae tipa b), HIB- HBV (cepivo proti Haemophilus influenzae tipa b in hepatitisu B) ter VAR (norice).
Currently no specific studies have been conducted on the concomitant use of M-M-RVAXPRO and other vaccines.
V zadnjem času specifičnih študij o sočasnem cepljenju z M- M- RVAXPRO in drugimi cepivi niso izvedli.
5 and rubella vaccine manufactured by Merck & Co., Inc., experience with this vaccine can be considered.
Ker pa ima M- M- RVAXPRO dokazano podoben profil varnosti in imunogenosti kot prejšnja oblika kombiniranega cepiva proti ošpicam, mumpsu in rdečkam proizvajalca Merck & Co., Inc., lahko upoštevamo izkušnje s tem cepivom.
M-M-RVAXPRO should be given concomitantly at separate injection sites, or one month before or after administration of other live virus vaccines.
Z M- M- RVAXPRO in drugimi cepivi z živimi virusi lahko cepimo sočasno, toda na različnih vbodnih mestih, ali pa en mesec pred ali en mesec po cepljenju z drugimi cepivi z živim virusom.
Studies have not been conducted with M-M-RVAXPRO in pregnant women.
Študij o cepljenju z M- M- RVAXPRO pri nosečnicah niso izvedli.
It is not known whether M-M-RVAXPRO can cause foetal harm when administered to a pregnant woman or can affect reproduction capacity.
Ni znano, ali lahko M- M - RVAXPRO škoduje plodu, če z njim cepimo nosečnico, in ali vpliva na sposobnost razmnoževanja.
Therefore, the vaccine should not be administered to pregnant females; furthermore, pregnancy should be avoided for 3 months following vaccination (see sections 4.3 and 4.4).
Poleg tega naj ženska 3 mesece po cepljenju ne zanosi (glejte poglavji 4. 3 in 4. 4).
In order to advise women who are inadvertently vaccinated when pregnant or who become pregnant within 3 months of vaccination, the physician should be aware of the following:
Pri svetovanju ženskam, ki so pomotoma cepljene v nosečnosti ali ki zanosijo v 3 mesecih po cepljenju, se mora zdravnik zavedati teh dejstev:
(1) In a 10 year survey involving over 700 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 189 received the Wistar RA 27/ 3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome; (2) Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion.
(1) V desetletni študiji, ki je zajela več kot 700 nosečnic, ki so bile v 3 mesecih pred ali po zanositvi cepljene proti rdečkam (med njimi jih je bilo 189 cepljenih s sevom Wistar RA 27/ 3), ni imel noben novorojenček prirojenih okvar, ki bi ustrezale sindromu prirojenih rdečk; (2) Okužba z mumpsom v prvem trimesečju nosečnosti lahko poveča delež spontanih splavov.
Although mumps vaccine virus has been shown to infect the placenta and foetus, there is no evidence that it causes congenital malformations in humans; and (3) Reports have indicated that contracting wild-type measles during pregnancy enhances foetal risk.
Čeprav so za virus mumpsa dokazali, da okuži posteljico in plod, ni dokazov, da pri ljudeh povzroča prirojene napake; ter (3) Poročila so pokazala, da okužba z divjim sevom ošpic med nosečnostjo poveča tveganje za plod.
Increased rates of spontaneous abortion, stillbirth, congenital defects, and prematurity have been observed subsequent to wild-type measles during pregnancy.
Po okužbi z divjim sevom ošpic med nosečnostjo so ugotavljali večji delež spontanih splavov, mrtvorojenosti, prirojenih napak in prezgodnjih porodov.
There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy.
5 Ustreznih študij o oslabljenem (cepilnem) sevu virusa ošpic v nosečnosti ni.
However, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse foetal effects.
Razumno pa bi bilo predvidevati, da lahko tudi cepilni sev virusa škodljivo vpliva na plod.
Official recommendations may vary regarding the duration of the waiting period that is recommended for avoiding pregnancy following vaccination.
Opomba: uradna priporočila lahko navajajo različna obdobja, ko se je po cepljenju treba izogibati nosečnosti.
Postpartum Women It has been found convenient in many instances to vaccinate rubella-susceptible women in the immediate postpartum period.
Ženske po porodu V mnogih primerih se je za umestno pokazalo cepljenje žensk, dovzetnih za rdečke, v zgodnjem poporodnem obdobju.
Studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breast-fed infants.
Študije so pokazale, da lahko doječe matere, ki so bile po porodu cepljene z živim oslabljenim cepivom proti rdečkam, izločajo virus v mleku in ga prenesejo na dojenčke.
It is not known whether measles or mumps vaccine virus is secreted in human milk; therefore, caution should be exercised when M-M-RVAXPRO is administered to a breast-feeding woman.
Zato je pri odločitvi o cepljenju doječe matere s cepivom M- M- RVAXPRO potrebna previdnost.
In clinical trials, M-M-RVAXPRO was administered to 1965 children (see section 5.1), and the general safety profile was comparable to the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc.
Splošni profil varnosti je bil primerljiv s prejšnjo obliko cepiva proti ošpicam, mumpsu in rdečkam proizvajalca Merck & Co., Inc.
The general safety profile of either administration routes were comparable,
V kliničnem preskušanju je bilo s cepivom M- M- RVAXPRO intramuskularno (i. m.) ali subkutano (s. c.) cepljenih 752 otrok.
6 although injection-site reactions were less frequent in the IM group (15.8%) compared with the SC group (25.8%).
Splošni profil varnosti po obeh načinih injiciranja je bil primerljiv, čeprav so bile reakcije na mestu vboda manj pogoste pri i. m. uporabi (15%) v primerjavi s s. c. uporabo (25, 8%).
All adverse reactions were evaluated in 1940 children.
Vse neželene učinke so ocenili pri 1940 otrocih.
Among these children, the following vaccine-related adverse reactions were observed in individuals following vaccination with M-M-RVAXPRO (excluding isolated reports with frequency < 0.2%).
Med temi otroci so po cepljenju z M- M- RVAXPRO opazili te, s cepljenjem povezane, neželene učinke (razen posameznih poročil s pojavnostjo < 0, 2%).
In comparison to the first dose, a second dose of M-M-RVAXPRO is not associated with an increase in the incidence and severity of clinical symptoms including those suggestive of hypersensitivity reaction.
V primerjavi s prvim odmerkom drugi odmerek cepiva M- M- RVAXPRO ni povezan s povečano pojavnostjo in jakostjo kliničnih simptomov, vključno tistih, ki nakazujejo preobčutljivostno reakcijo.
Additionally, other adverse experiences reported with post-marketing use of M-M-RVAXPRO and/ or in clinical studies and post-marketing use of previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck & Co., Inc. without regard to causality or frequency are available and are summarised below (frequency not known).
Dodatno so na voljo podatki o neželenih učinkih iz obdobja trženja cepiva M- M- RVAXPRO in/ ali iz kliničnih študij in iz obdobja trženja prejšnjih oblie enovalentnih in kombiniranih cepiv proti ošpicam, mumpsu in rdečkam proizvajalca Merck & Co., Inc. in so, ne glede na vzročnost ali pogostnost pojavljanja, našteti spodaj (pogostnost pojavljanja ni znana).
[Very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to ≤ 1/ 100); not known (cannot be estimated from the available data)]
[Zelo pogosti (≥ 1/ 10), pogosti (≥ 1/ 100 do < 1/ 10), občasni (≥ 1/ 1. 000 do < 1/ 100); neznani (ni mogoče oceniti iz razpoložljivih podatkov)]
Infections and infestations Uncommon: nasopharyngitis, upper respiratory tract infection or viral infection Not known: aseptic meningitis (see below), atypical measles, epididymitis, orchitis, otitis media, parotitis, rhinitis, subacute sclerosing panencephalitis (see below)
Infekcijske in parazitske bolezni Občasne: nazofaringitis, okužba zgornjih dihal ali virusna okužba Neznana pogostnost: aseptični meningitis (glejte v nadaljevanju), atipične ošpice, epididimitis, orhitis, vnetje srednjega ušesa, parotitis, rinitis, subakutni sklerozirajoči panencefalitis (glejte v nadaljevanju).
Blood and the lymphatic system disorders Not known: regional lymphadenopathy, thrombocytopenia
6 Neznana pogostnost: regionalna limfadenopatija, trombocitopenija
Immune system disorders Not known: anaphylactoid reaction, anaphylaxis and related phenomenon such as angioneurotic oedema, facial oedema, and peripheral oedema
Bolezni imunskega sistema Neznana pogostnost: anafilaktoidna reakcija, anafilaksija in povezani pojavi, kot so angionevrotični edem, obrazni edem in periferni edem
Psychiatric disorders Not known: irritability
Psihiatrične bolezni Neznana pogostnost: razdražljivost
Nervous system disorders Not known: afebrile convulsions or seizures, ataxia, dizziness, encephalitis (see below), encephalopathy (see below), febrile convulsion (in children), Guillain-Barre syndrome, headache, measles inclusion body encephalitis (MIBE) (see section 4.3), ocular palsies, optic neuritis, paraesthesia, polyneuritis, polyneuropathy, retrobulbar neuritis, syncope
Bolezni živčevja Neznana pogostnost: nevročinski krči ali napadi, ataksija, vrtoglavica, encefalitis (glejte v nadaljevanju), encefalopatija (glejte v nadaljevanju), vročinski krči (pri otrocih), Guillain- Barréjev sindrom, glavobol, ošpični encefalitis z inkluzijskimi telesci (MIBE – » measles inclusion body encephalitis «) (glejte poglavje 4. 3), očesne pareze, optični nevritis, parestezija, polinevritis, polinevropatija, retrobulbarni nevritis, sinkopa
Encephalitis and encephalopathy, excluding subacute sclerosing panencephalitis (SSPE), have been reported approximately once for every 3 million doses of the measles-containing vaccines manufactured by Merck & Co., Inc.
O encefalitisu in encefalopatiji (razen subakutnega sklerozirajočega panencefalitisa [SSPE – subacute sclerosing panencephalitis «]) so poročali približno enkrat na 3 milijone odmerkov cepiva, ki vsebuje cepivo proti ošpicam proizvajalca Merck & Co., Inc.